Psyence Biomedical (PBM) said Wednesday it has received extension from Nasdaq through Dec. 31 for demonstrating compliance with all continued listing requirements.
During the hearing, the company provided a plan to the regulator regarding compliance with listing requirements including the $1 minimum bid price rule, the $1 million market value, and the $2.5 million minimum shareholders' equity requirement, Psyence added.
The life science biotechnology company has also asked the regulator to shift it to the Nasdaq Capital Market from the Nasdaq Global Market.
Additionally, Psyence said it received shareholder nod on Nov. 12 for a 1-for-75 share consolidation plan to meet the $1 minimum bid price requirement.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。